New combo therapy targets Gene-Mutated lung cancer
NCT ID NCT01221077
First seen Nov 18, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) helps people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. 88 participants who had not received prior chemotherapy were randomly assigned to receive either the combination or erlotinib alone. The main goal was to see if the combination delayed cancer growth better than the standard treatment alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Songpa-gu, Seoul, 138736, South Korea
-
Chonnam National University Hwasun Hospital
Ilsimri, Hwasun-gun, 519809, South Korea
-
Cleveland Clinic Florida
Weston, Florida, 33331, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
Johns Hopkins Singapore International Medical Centre
Singapore, 308433, Singapore
-
Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Khon Kaen University
Khon Kaen, 40002, Thailand
-
Korea University Anam Hospital
Seoul, 136705, South Korea
-
London Regional Cancer Program
London, Ontario, N6A 4L6, Canada
-
Maharaj Nakorn Chiangmai
Chiang Mai, 50002, Thailand
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
National Cancer Institute
Phayathai, Bangkok, 10400, Thailand
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
-
Oncocare Cancer Center
Singapore, 258499, Singapore
-
Pamela Youde Nethersole Eastern Hospital
Chai Wan, 852, Hong Kong
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Samsung Medical Center
Seoul, 135710, South Korea
-
Seattle Cancer Care Alliance University of Washington
Seattle, Washington, 98109, United States
-
Seoul National University Bundang Hospital
Seongnam-si, 463-707, South Korea
-
Songklanagarind Hospital, Prince of Songkla University
Songkhla, 90110, Thailand
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
University of California, San Diego/Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Tennessee Cancer Institute
Memphis, Tennessee, 31804, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.